Related Experiment Video
Updated: Sep 23, 2026

Software-Assisted Quantitative Measurement of Osteoarthritic Subchondral Bone Thickness
Published on: March 18, 2022
Punicic acid alleviates osteoarthritis progression through miR-29a-3p-dependent inhibition of the MAP2K6/p38 MAPK
Wei Wang1, Tao Zhang2, Chao Yu2
1The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, No.41 Linyin Road, Baotou, 014000, Inner Mongolia, China.
Abstract:
Osteoarthritis (OA) is a chronic degenerative joint disease characterized by progressive articular cartilage degradation. Punicic acid (PA), a plant-derived n-3 polyunsaturated fatty acid, has been reported to exert anti-inflammatory and anti-apoptotic effects. However, the molecular mechanisms underlying its effects in OA remain incompletely understood. In this study, bioinformatics analysis was performed to identify apoptosis-related differentially expressed genes (DEGs) and enriched signaling pathways associated with OA. An in vitro OA-like model was established using interleukin-1β (IL-1β)-stimulated SW1353 cells, which were subsequently treated with different concentrations of PA. PA suppressed IL-1β-induced expression of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), matrix metalloproteinase-3 (MMP-3),matrix metalloproteinase-13 (MMP-13), and A Disintegrin And Metalloproteinase with Thrombospondin Motifs 5 (ADAMTS-5) and attenuated apoptosis by modulating Bcl-2-associated X protein (BAX) and B-cell lymphoma 2 (BCL-2) expression. Notably, target prediction and dual-luciferase reporter assays confirmed that mitogen-activated protein kinase kinase 6 (MAP2K6) is a direct target of microRNA-29a-3p (miR-29a-3p), and PA increased miR-29a-3p expression in the in vitro OA-like model. Furthermore, PA inhibited MAP2K6-mediated activation of the p38 mitogen-activated protein kinase (p38 MAPK) pathway, thereby attenuating downstream inflammatory and apoptotic signaling. These findings suggest that PA exerts chondroprotective effects by modulating the miR-29a-3p/MAP2K6/p38 MAPK signaling axis, highlighting its therapeutic potential and supporting the development of miRNA-based therapeutic strategies for OA.